Endotel Disfonksiyonunun Bir Belirteci; Endokan
Özet
Endotel, vasküler hemostazın korunmasında hayati bir rol oynayan, damarların iç yüzeyini kaplayan geniş bir metabolik organdır. Bu dokunun fonksiyonlarını yerine getirememesi sonucu gelişen endotel disfonksiyonu; başta ateroskleroz, hipertansiyon ve diyabet olmak üzere pek çok kardiyovasküler hastalığın temelini oluşturmaktadır. Endokan (ESM-1), 1996 yılında tanımlanan ve özellikle aktive olmuş vasküler endotelden salgılanan proteoglikan yapıda yeni bir biyobelirteçtir. Bu molekül; lökosit adezyonu, enflamasyon, anjiyogenez ve vasküler geçirgenlik gibi süreçlerde kritik bir modülatör olarak görev yapar. Klinik çalışmalar, serum endokan düzeylerinin sistemik enflamasyon ve endotel aktivasyonunun güçlü bir göstergesi olduğunu ortaya koymaktadır. Hipertansiyon hastalarında endokan seviyeleri damar sertliği ile pozitif korelasyon gösterirken, kronik böbrek yetmezliğinde hastalığın evresiyle birlikte artış sergilemektedir. Ayrıca sepsiste şiddet belirteci, kanserlerde ise tümör vaskülarizasyonu ve agresifliğiyle ilişkili bir prognostik faktör olarak dikkat çekmektedir. Henüz rutin klinik uygulamaya girmemiş olsa da endokan; vasküler patolojilerin erken teşhisi, risk sınıflandırması ve tedavi takibinde yüksek potansiyele sahip stratejik bir biyobelirteç adayıdır.
The endothelium is a vast metabolic organ lining the inner surface of vessels that plays a vital role in maintaining vascular homeostasis. Endothelial dysfunction, which occurs when this tissue fails to perform its functions, forms the basis of many cardiovascular diseases, primarily atherosclerosis, hypertension, and diabetes. Endocan (ESM-1), identified in 1996, is a novel proteoglycan-structured biomarker secreted specifically from the activated vascular endothelium. This molecule serves as a critical modulator in processes such as leukocyte adhesion, inflammation, angiogenesis, and vascular permeability. Clinical studies reveal that serum endocan levels are a potent indicator of systemic inflammation and endothelial activation. While endocan levels show a positive correlation with vascular stiffness in hypertensive patients, they exhibit an increase alongside the disease stage in chronic kidney failure. Furthermore, it stands out as a severity marker in sepsis and a prognostic factor associated with tumor vascularization and aggressiveness in cancers. Although not yet in routine clinical use, endocan is a strategic biomarker candidate with high potential for early diagnosis, risk stratification, and treatment monitoring of vascular pathologies.
Referanslar
Gürel E. The Functions of the Endothelium and its Relationship with Diseases: Review. T Klinik Card Sci. 2009;21: 423-33.
Augustin H, Kozian D, Johnson R. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays. 1994;16(12): 901-6. doi:10.1002/bies.950161208
Günel T, Göksever Çelik H, Küçükkaya R, et al. İnsan Hastalıklarında Endotel Fonksiyon ve Disfonksiyonunun Moleküler Mekanizmaları. İst Kan Sult Süleym Tıp D. 2020;12(3): 201-216. doi:10.5222/iksstd.2020.61587
Cho JG, Lee A, Chang W, et al. Endothelial to Mesenchymal Transition Represents a Key Link in the Interaction between Inflammation and Endothelial Dysfunction. Front Immunol. 2018;9: 294. doi:10.3389/fimmu.2018.00294
Zhang S, Zuo L, Zhou Q, et al. Expression and distribution of endocan in human tissues. Biotech & Histoch. 2012;87(3): 172-8. doi:10.3109/10520295.2011.577754
Furchgott R, Zawadzki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789): 373-6. doi:10.1038/288373a0
Francis S, Busch J, Corbin J, et al.. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3): 525-63. doi:10.1124/pr.110.002907
Félétou M, Vanhoutte P. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291(3): H985-1002. doi:10.1152/ajpheart.00292.2006
Balta S, Balta I, Mikhailidis D. Endocan: a new marker of endothelial function. Curr Opin Cardiol. 2021;36(4): 462-8. doi:10.1097/hco.0000000000000867
Leite A, Borges-Canha M, Cardoso R, et al.. Novel Biomarkers for Evaluation of Endothelial Dysfunction. Angiol. 2020;71(5): 397-410. doi:10.1177/0003319720903586
Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423): 801-9. doi:10.1038/362801a0
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circul. 2004;109(23 Suppl 1): iii27-32. doi:10.1161/01.CIR.0000131515.03336.f
Panza JA, Casino PR, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J of the Am Coll of Card. 1994;23(7): 1610-6. https://doi.org/10.1016/0735-1097(94)90664-5
Kawano H, Motoyama T, Hirai N, et al. Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: possible role of oxidative stress. Atherosc. 2002;161(2): 375-80. doi:10.1016/s0021-9150(01)00671-2
Kali A, Shetty K. Endocan: a novel circulating proteoglycan. Ind J Pharmacol. 2014;46(6): 579-83. doi:10.4103/0253-7613.144891
Delehedde M, Devenyns L, Maurage C, et al. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol. 2013;2013: 705027. doi:10.1155/2013/705027
Balta S, Mikhailidis DP, Demirkol S, et al. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosc. 2015;243(1): 339-43. doi:10.1016/j.atherosclerosis.2015.09.030
Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765(1): 25-37. doi:10.1016/j.bbcan.2005.08.004
Çimen T, Efe T, Akyel A, et al. Human Endothelial Cell-Specific Molecule-1 (Endocan) and Coronary Artery Disease and Microvascular Angina. Angiol. 2016;67(9): 846-53. doi:10.1177/0003319715625827
Tadzic R, Mihalj M, Vcev A, et al. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kid Blo Press Res. 2013;37(2-3): 103-15. doi:10.1159/000350064
Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167(6): 3099-106. doi:10.4049/jimmunol.167.6.3099
Lee H, Choi H, Bae J. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kid Int. 2014;86(6): 1079-81. doi:10.1038/ki.2014.292
Balta S, Demirkol S, Celik T, et al. Association between coronary artery ectasia and neutrophil-lymphocyte ratio. Angiol. 2013;64(8): 627-32. doi:10.1177/0003319713480424
Sarrazin S, Maurage C, Delmas D, et al. Endocan as a biomarker of endothelial dysfunction in cancer. J Canc Sci Ther. 2010;2(2): 47-52.
Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan Concentration in Patients With Primary Hypertension. Angiol. 2018;69(6): 483-9. doi:10.1177/0003319717736158
Karaman M, Balta S, Seyit Ahmet A, et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013;35(7): 516-22. doi:10.3109/10641963.2012.758734
Balta S, Mikhailidis DP, Demirkol S, et al. Endocan and atherosclerosis. Angiol. 2015;66(5): 490. doi:10.1177/0003319715568973
Kellum J, Lameire N, Aspelin P, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. Kid Int Supp. 2012;2(1): 1. doi:10.1038/kisup.2012.1
Kellum J, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1): 204. doi:10.1186/cc11454
Nalewajska M, Gurazda K, Marchelek-Myśliwiec M, et al. The Role of Endocan in Selected Kidney Diseases. Int J Mol Sci. 2020; 21(17). doi:10.3390/ijms21176119
Rahmania L, Cortés DO, Irazabal M, et al. Elevated endocan levels are associated with development of renal failure in ARDS patients. J Int Care Med Exp. 2015;3(1): 1-2.
Su YH, Shu KH, Hu CP, et al. Serum Endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transp Proc. 2014;46(2): 323-7. doi:10.1016/j.transproceed.2013.10.057
Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kid Int. 2014;86(6): 1213-20. doi:10.1038/ki.2014.227
Ekiz-Bilir B, Bilir B, Aydın M, et al. Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. Arch Med Sci. 2019;15(1): 86-91. doi:10.5114/aoms.2018.79488
Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5): 1066-70. doi:10.1111/bjd
Aciksari G, Kavas M, Atici A, et al. Endocan Levels and Endothelial Dysfunction in Patients With Sarcoidosis. Angiol. 2018;69(10): 878-83. doi:10.1177/0003319718775283
Mihajlovic D, Brkic S, Lendak D, et al. Endothelial biomarkers in the light of new sepsis definition. Bio Med. 2019;13(5): 341-51. doi:10.2217/bmm-2018-0282
Mihajlovic DM, Lendak DF, Brkic SV, et al. Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res. 2014;93: 92-7. doi:10.1016/j.mvr.2014.04.004
Huang X, Chen C, Wang X, et al. Prognostic value of endocan expression in cancers: evidence from meta-analysis. Onco Targ Ther. 2016;9: 6297-304. doi:10.2147/ott.S110295
Maurage CA, Adam E, Minéo JF, et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 2009;68(6): 633-41. doi:10.1097/NEN.0b013e3181a52a7f
Li C, Geng H, Ji L, Ma X, et al. ESM-1: A Novel Tumor Biomaker and its Research Advances. Anticancer Ag Med Chem. 2019;19(14): 1687-94. doi:10.2174/1871520619666190705151542
